These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12705166)

  • 61. The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results.
    Toprak MK; Cakir B; Ulu EM; Arat Z; Benli US; Can U; Ağildere M
    Int J Neurosci; 2008 Dec; 118(12):1645-58. PubMed ID: 18937112
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The treatment of multiple sclerosis with beta-interferon.
    Poser CM
    Neuroepidemiology; 2008; 31(3):157-8. PubMed ID: 18716413
    [No Abstract]   [Full Text] [Related]  

  • 63. Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis?
    Oger J; Gibbs E
    Nat Clin Pract Neurol; 2006 Feb; 2(2):76-7. PubMed ID: 16932528
    [No Abstract]   [Full Text] [Related]  

  • 64. Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy.
    Pulicken M; Koteish A; DeBusk K; Calabresi PA
    Neurology; 2006 Jun; 66(12):1954-5. PubMed ID: 16801674
    [No Abstract]   [Full Text] [Related]  

  • 65. Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment.
    Dionisiotis J; Zoukos Y; Thomaides T
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1079. PubMed ID: 15201386
    [No Abstract]   [Full Text] [Related]  

  • 66. 10 years of interferon beta-1b (Beta feron therapy.
    Kappos L; Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii1-iii2. PubMed ID: 16170493
    [No Abstract]   [Full Text] [Related]  

  • 67. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.
    Strueby L; Nair B; Kirk A; Taylor-Gjevre RM
    Scand J Rheumatol; 2005; 34(6):485-8. PubMed ID: 16393774
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Drug treatment of multiple sclerosis. Clinical review was unsystematic.
    Milne R; Clegg A; Bryant J
    BMJ; 2001 Feb; 322(7281):299. PubMed ID: 11157552
    [No Abstract]   [Full Text] [Related]  

  • 69. Administering Betaseron for MS.
    Piascik P
    Am Pharm; 1994 Jan; NS34(1):21-2. PubMed ID: 8166031
    [No Abstract]   [Full Text] [Related]  

  • 70. Will public health survive QALYs?
    Heller JG
    Can J Clin Pharmacol; 2002; 9(1):5-6. PubMed ID: 11919640
    [No Abstract]   [Full Text] [Related]  

  • 71. Improving adherence to injectable disease-modifying drugs in multiple sclerosis.
    Bayas A
    Expert Opin Drug Deliv; 2013 Mar; 10(3):285-7. PubMed ID: 23339371
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multiple sclerosis risk sharing scheme: a costly failure.
    Raftery J
    BMJ; 2010 Jun; 340():c1672. PubMed ID: 20522654
    [No Abstract]   [Full Text] [Related]  

  • 73. MS risk sharing scheme. Some clarification needed.
    Richards RG
    BMJ; 2010 Jul; 341():c3589. PubMed ID: 20610505
    [No Abstract]   [Full Text] [Related]  

  • 74. Multiple sclerosis drug prompts rationing fears.
    Dyer O
    BMJ; 1995 Oct; 311(7011):969. PubMed ID: 7580631
    [No Abstract]   [Full Text] [Related]  

  • 75. Interferon beta in multiple sclerosis.
    Napier JC
    Lancet; 1999 Aug; 354(9177):512; author reply 512-3. PubMed ID: 10465197
    [No Abstract]   [Full Text] [Related]  

  • 76. [Guidelines of the consensus conference on multiple sclerosis].
    French Federation of Neurology, with participation of l'AEAES.
    Rev Neurol (Paris); 2001 Jul; 157(6-7):713-21. PubMed ID: 11458194
    [No Abstract]   [Full Text] [Related]  

  • 77. [Early immunomodulatory treatment of multiple sclerosis. Economic aspects].
    Czapliński A
    Neurol Neurochir Pol; 2001; 35(5):957-60. PubMed ID: 11873608
    [No Abstract]   [Full Text] [Related]  

  • 78. A robust mixed linear model analysis for longitudinal data.
    Gill PS
    Stat Med; 2000 Apr; 19(7):975-87. PubMed ID: 10750063
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Interferon beta in multiple sclerosis.
    Gross M
    Lancet; 1999 Aug; 354(9177):512; author reply 512-3. PubMed ID: 10465198
    [No Abstract]   [Full Text] [Related]  

  • 80. Funding medicines for people with multiple sclerosis.
    Taylor D
    BMJ; 2001 Dec; 323(7326):1379-80. PubMed ID: 11744549
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.